Oncotarget

Research Papers:

Down-regulation of UBC9 increases the sensitivity of hepatocellular carcinoma to doxorubicin

Sufen Fang, Junyao Qiu, Zheng Wu, Tao Bai and Wuhua Guo _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:49783-49795. https://doi.org/10.18632/oncotarget.17939

Metrics: PDF 1002 views  |   HTML 1277 views  |   ?  


Abstract

Sufen Fang2,*, Junyao Qiu2,*, Zheng Wu2, Tao Bai2 and Wuhua Guo1

1Department of Interventional Radiology, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, China

2Department of Gastroenterology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, China

*These authors have contributed equally to this work

Correspondence to:

Wuhua Guo, email: guowuhua@aliyun.com

Keywords: UBC9, SUMOylation, hepatocellular carcinoma (HCC), doxorubicin (DOX), apoptosis

Received: December 20, 2016     Accepted: May 05, 2017     Published: May 17, 2017

ABSTRACT

UBC9 is an E2-conjugating enzyme that is required for SUMOylation and has been implicated in regulating several critical cellular pathways. UBC9 is overexpressed in certain tumors, such as lung adenocarcinoma, ovarian carcinoma and melanoma, which implies that it has special clinical significance. However, the role of UBC9 in Hepatocellular carcinoma (HCC) drug responsiveness is not clear. In this study, we investigated the clinicopathological significance of UBC9 in HCC and investigated the mechanism of UBC9-mediated chemosensitivity to doxorubicin (DOX) in hepatocellular carcinoma cells. We found that relative to adjacent normal tissues, UBC9 was markedly overexpressed in HCC, which closely correlated with tumor size, tumor microsatellite formation, and tumor encapsulation. Our results also showed that down-regulation of UBC9 by shRNA reduced the expression of Bcl-2 and Bcl-xl and increased the expression of cleaved-Caspase3, which is a proapoptotic protein. These changes were associated with reduced apoptosis in response to DOX. Furthermore, we observed a mechanism involving modulation of the P38 and ERK1/2 signaling pathways. Together, our results indicate that down-regulation of UBC9 sensitizes cells to anticancer drugs, is possibly associated with the regulation of ERK1/2 and P38 activation and interacts with the intrinsic apoptosis pathway. Thus, knockdown of UBC9 may have a tumor suppressor effect and UBC9 could be a potential target for the treatment of HCC cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17939